Horizon Therapeutics plc
https://www.horizontherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Horizon Therapeutics plc
Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
Lots To Celebrate Among 2021 Drug Launches, But Underlying Trends Underwhelm
The number of new drugs that launched in 2021 was on par with recent high trends, but launch trajectories generally underwhelmed commercially – except for COVID-19 vaccines.
Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
Deal Watch: BMS Licenses Bispecific TCR Candidate From Immatics
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Bio-Technology General Corporation
- Crealta Holdings LLC
- Crealta Pharmaceuticals
- Curzion Pharmaceuticals, Inc.
- Encode Pharmaceuticals, Inc.
- Horizon Pharma plc
- Hyperion Therapeutics, Inc. (Andromeda Biotech Ltd)
- Nitec Pharma AG
- Raptor Pharmaceutical Corp.
- River Vision Development Corp.
- Savient Pharmaceuticals, Inc. (SVNT)
- TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
- Vidara Therapeutics Inc
- Viela Bio, Inc.